Literature DB >> 22565001

Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma.

Robert G Maki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22565001     DOI： 10.1200/JCO.2012.42.3285

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy.

Authors:  Sarah E Ballatori; Philip W Hinds
Journal:  Signal Transduct Target Ther       Date:  2016-03-25

2.  An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.

Authors:  Katherine E Hill; Andrew D Kelly; Marieke L Kuijjer; William Barry; Ahmed Rattani; Cassandra C Garbutt; Haydn Kissick; Katherine Janeway; Antonio Perez-Atayde; Jeffrey Goldsmith; Mark C Gebhardt; Mohamed S Arredouani; Greg Cote; Francis Hornicek; Edwin Choy; Zhenfeng Duan; John Quackenbush; Benjamin Haibe-Kains; Dimitrios Spentzos
Journal:  J Hematol Oncol       Date:  2017-05-15       Impact factor: 17.388

3.  Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study.

Authors:  Xiaoyi Huang; Jian Zhao; Jinyi Bai; Hua Shen; Bingbing Zhang; Lulu Deng; Chen Sun; Yanfang Liu; Jing Zhang; Jianming Zheng
Journal:  J Bone Oncol       Date:  2019-03-07       Impact factor: 4.072

4.  MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.

Authors:  Christopher E Lietz; Cassandra Garbutt; William T Barry; Vikram Deshpande; Yen-Lin Chen; Santiago A Lozano-Calderon; Yaoyu Wang; Brian Lawney; David Ebb; Gregory M Cote; Zhenfeng Duan; Francis J Hornicek; Edwin Choy; G Petur Nielsen; Benjamin Haibe-Kains; John Quackenbush; Dimitrios Spentzos
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.